Cell rejuvenation technology, in which Silicon Valley billionaires are investing hundreds of millions of dollars, has shown promising results for the first time in clinical trials on humans. The American biotechnology company Life Biosciences has reported that the experimental gene therapy ER-100 improved certain aspects of vision in two out of three patients with glaucoma. The research is based on partial cellular reprogramming technology, which aims to restore the functions of damaged cells. Well-known investors in the longevity sector include Jeff Bezos, Peter Thiel, Sam Altman and Yuri Milner. However, scientists emphasise that these initial results do not yet prove it is possible to halt human ageing or restore the body to a youthful state.<\/p>\n
Briefly about the main points<\/strong><\/p>\n An American company Life Biosciences<\/strong> On 8 October 2026, the company presented preliminary results from the first phase of the clinical trial of the experimental therapy ER-100. It is being developed to treat optic nerve disorders, in particular open-angle glaucoma, which can cause irreversible vision loss.<\/p>\n Three patients took part in the first phase. Each was given an injection of the experimental drug directly into the eye, after which they took doxycycline daily for eight weeks. In this protocol, the antibiotic is used to activate genetic factors that are intended to alter the state of the cells.<\/p>\n In 56 days\u2019 time The researchers observed signs of an improvement in visual field in two participants<\/strong>. In each case, at least 28% verified points demonstrated an increase in light sensitivity of more than four decibels.<\/p>\n According to the company, the drug was well tolerated by all three patients. No serious adverse reactions related to the treatment were recorded during the first eight weeks. An independent safety monitoring committee recommended proceeding to a higher-dose trial.<\/p>\n However, this is only the first phase of a study involving three people. These results are not sufficient to confirm the treatment\u2019s effectiveness or to prove that the tissues have actually been rejuvenated.<\/p>\n Partial epigenetic reprogramming forms the basis of this experimental treatment. The method aims to alter gene activity in cells without altering the DNA sequence itself.<\/p>\n As cells age, they gradually accumulate changes in their gene regulation mechanisms, which can affect their ability to function normally and regenerate. Researchers are attempting to partially restore these mechanisms to a state typical of younger cells.<\/p>\n The ER-100 therapy utilises three reprogramming factors \u2014 OCT4, SOX2 and KLF4. These belong to the so-called Yamanaka factors, the discovery of which was one of the most significant achievements in modern cell biology.<\/p>\n Unlike complete reprogramming, which can transform mature cells into stem cells, the partial approach is designed to preserve their specialisation. It is precisely this that should help to reduce the risk of undesirable changes, although the long-term safety of the technology still needs to be investigated.<\/p>\n Previous animal experiments have demonstrated that it is possible to influence certain age-related changes. However, results from mice and other laboratory models do not guarantee a similar effect in humans.<\/p>\n Interest in longevity technologies has long since extended beyond the confines of academic laboratories. In Silicon Valley, a whole industry of biotechnology start-ups has emerged, researching ways to regenerate cells, treat age-related diseases and extend healthy life expectancy.<\/p>\n One of the best-known projects is Altos Labs, which is backed by the founder of Amazon Jeff Bezos<\/strong>. The company began operations with funding of approximately $3 billion and focused on research into cell reprogramming.<\/p>\n\n
Cell rejuvenation has been tested on humans for the first time in the US<\/h2>\n
How does the technology that is supposed to restore youthfulness to cells work?<\/h2>\n
Bezos, Thiel and Altman are investing hundreds of millions in life extension<\/h2>\n